Clinical Trials · NCT03233178
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
- Enrollment
- 4,000
- Start date
- Jan 2017
- Locations
- 1 site, Canada
- Primary endpoint
- Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control